Scented foot massage may soothe diabetic nerve pain
NCT ID NCT07271160
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether aromatherapy foot massage can reduce neuropathic pain in people with type 2 diabetes. 78 participants will massage their feet for 10 minutes, three times a week for 4 weeks. Researchers will compare the effects of an aromatherapy oil versus a plain oil to see if the scent adds any benefit.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- aromatherapy foot massage
- What this could lead to
- If it works, this could offer a simple, drug-free way to reduce nerve pain in people with type 2 diabetes.
- What could go wrong
- This is a small, early-stage trial with no blinding, so results may be influenced by placebo effects. The massage is self-administered, which may lead to inconsistent technique.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 78 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Dec 2025
An estimate. Start dates often move.
- Expected to finish
-
May 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients with a Douleur neuropathic pain questionnaire score of 4 and above, * 18 years and over, * No psychiatric illness, * Patients who are able to answer all the questions, * Turkish-speaking patients. Exclusion Criteria: * Patients who cannot be contacted, * Any limb, vascular problem or wound that prevents the application of foot massage, * Thrombophlebitis, occlusive arterial disease, fever, etc. Those who are inconvenient to massage due to illness, * Patients who refused to participate in the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diabetic neuropathy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Nevsehir State Hospital
Nevşehir, Nevşehir Province, 50100, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists map the daily rhythms of chronic pain
- Four pills, one goal: can a new combo tame type 2 diabetes?
- Can zapping two brain regions at once quiet chronic nerve pain?
- Can banding the gut tame type 2 diabetes?
- Can QR codes and videos teach better foot care?
- Can a new injection help tackle obesity? a trial puts MWN105 to the test